Home / Business and Economy / Sun Pharma Q3 Profits Soar 16% on Strong Revenue Growth
Sun Pharma Q3 Profits Soar 16% on Strong Revenue Growth
31 Jan
Summary
- Consolidated net profit rose 16.03% to Rs 3,368.81 crore in Q3 FY26.
- Total revenue increased by 13.49% to Rs 15,520.54 crore in Q3 FY26.
- The company declared an interim dividend of Rs 11 per equity share.
Sun Pharmaceutical Industries reported a robust third quarter for FY26, with consolidated net profit surging by 16.03% to Rs 3,368.81 crore. This notable increase was accompanied by a 13.49% rise in revenue, which reached Rs 15,520.54 crore over the same period in FY25. Profit before tax also saw a significant increase of 21.59%.
Domestic formulation sales in India demonstrated strong momentum, growing by 16.2% and constituting 32.3% of total consolidated sales. The US market showed marginal growth in formulation sales, with innovative medicines offsetting declines in generics. Emerging Markets and Rest of World markets also recorded healthy growth rates.
The company's focus on innovative medicines continues to drive growth, with global sales of innovative medicines increasing by 13.2% excluding a milestone income. Sun Pharma's R&D pipeline remains a key strategic area, with ongoing investments in both innovative and generic businesses.
